{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:53:21Z","timestamp":1793894001477,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T00:00:00Z","timestamp":1340668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00228-012-1323-5","type":"journal-article","created":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T20:24:50Z","timestamp":1341865490000},"page":"197-207","source":"Crossref","is-referenced-by-count":9,"title":["High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension"],"prefix":"10.1007","volume":"69","author":[{"given":"A. M.","family":"Sandqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Henrohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schneede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hedeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. C.","family":"Eger\u00f6d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. G.","family":"Bondesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. G.","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,26]]},"reference":[{"issue":"16","key":"1323_CR1","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Moliterno DJ, Mukherjee D, Pohost GM, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ (2009) ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119(16):2250\u20132294","journal-title":"Circulation"},{"issue":"1 Suppl","key":"1323_CR2","first-page":"S43","volume":"54","author":"S Gr","year":"2009","unstructured":"Gr S, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing Z-C, Krowka MJ, Langleben D, Nakanishi N, Rr S (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54[1 Suppl]:S43\u2013S54","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1323_CR3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","volume":"183","author":"Z-C Jing","year":"2011","unstructured":"Jing Z-C, Yu Z-X, Shen J-Y, Wu B-X, Xu K-F, Zhu X-Y, Pan L, Zhang Z-L, Liu X-Q, Zhang Y-S, Jiang X, Gali\u00e8 N (2011) Vardenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study. Am J Resp Crit Care 183(11):1723\u20131729. doi: 10.1164\/rccm.201101-0093OC","journal-title":"Am J Resp Crit Care"},{"issue":"12 Suppl S","key":"1323_CR4","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","volume":"43","author":"M Humbert","year":"2004","unstructured":"Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43[12 Suppl S]:13S\u201324S","journal-title":"J Am Coll Cardiol"},{"issue":"1 Suppl","key":"1323_CR5","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","volume":"54","author":"NW Morrell","year":"2009","unstructured":"Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JXJ, Weir EK (2009) Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54[1 Suppl]:S20\u2013S31","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1323_CR6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jacc.2009.05.021","volume":"54","author":"V Melenovsky","year":"2009","unstructured":"Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, Kettner J, Kautzner J (2009) Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol 54(7):595\u2013600","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1323_CR7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1378\/chest.129.2.417","volume":"129","author":"JR Klinger","year":"2006","unstructured":"Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW (2006) Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 129(2):417\u2013425","journal-title":"Chest"},{"issue":"6","key":"1323_CR8","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","volume":"131","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6):1917\u20131928","journal-title":"Chest"},{"issue":"12 Suppl S","key":"1323_CR9","doi-asserted-by":"crossref","first-page":"68S","DOI":"10.1016\/j.jacc.2004.02.031","volume":"43","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43[12 Suppl S]:68S\u201372S","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1323_CR10","first-page":"1488","volume":"44","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44(7):1488\u20131496. doi: 10.1016\/j.jacc.2004.06.060","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1323_CR11","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Gali\u00e8","year":"2005","unstructured":"Gali\u00e8 N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Gr S (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353(20):2148\u20132157","journal-title":"N Engl J Med"},{"issue":"22","key":"1323_CR12","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22):2894\u20132903. doi: 10.1161\/CIRCULATIONAHA.108.839274","journal-title":"Circulation"},{"issue":"2","key":"1323_CR13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1378\/chest.07-2681","volume":"134","author":"J Suntharalingam","year":"2008","unstructured":"Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J (2008) Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 134(2):229\u2013236. doi: 10.1378\/chest.07-2681","journal-title":"Chest"},{"issue":"6\u20137","key":"1323_CR14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ejheart.2007.01.008","volume":"9","author":"A Jabbour","year":"2007","unstructured":"Jabbour A, Keogh A, Hayward C, Macdonald P (2007) Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Eur J Heart Fail 9(6\u20137):674\u2013677. doi: 10.1016\/j.ejheart.2007.01.008","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"1323_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCHEARTFAILURE.108.796789","volume":"1","author":"RJ Tedford","year":"2008","unstructured":"Tedford RJ, Hemnes AR, Russell SD, Wittstein IS, Mahmud M, Zaiman AL, Mathai SC, Thiemann DR, Hassoun PM, Girgis RE, Orens JB, Shah AS, Yuh D, Conte JV, Champion HC (2008) PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 1(4):213\u2013219. doi: 10.1161\/CIRCHEARTFAILURE.108.796789","journal-title":"Circ Heart Fail"},{"issue":"9337","key":"1323_CR16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","volume":"360","author":"HA Ghofrani","year":"2002","unstructured":"Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360(9337):895\u2013900. doi: 10.1016\/S0140-6736(02)11024-5","journal-title":"Lancet"},{"issue":"3","key":"1323_CR17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1378\/chest.06-2101","volume":"131","author":"HR Collard","year":"2007","unstructured":"Collard HR, Anstrom KJ, Schwarz MI, Zisman DA (2007) Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131(3):897\u2013899. doi: 10.1378\/chest.06-2101","journal-title":"Chest"},{"issue":"1","key":"1323_CR18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1183\/09031936.00124007","volume":"32","author":"MR Wilkins","year":"2008","unstructured":"Wilkins MR, Wharton J, Grimminger F, Ghofrani HA (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 32(1):198\u2013209. doi: 10.1183\/09031936.00124007","journal-title":"Eur Respir J"},{"issue":"6","key":"1323_CR19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuint.2004.03.016","volume":"45","author":"JD Corbin","year":"2004","unstructured":"Corbin JD, Beasley A, Blount MA, Francis SH (2004) Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 45(6):859\u2013863. doi: 10.1016\/j.neuint.2004.03.016","journal-title":"Neurochem Int"},{"issue":"18","key":"1323_CR20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/hrt.2009.169417","volume":"95","author":"ZC Jing","year":"2009","unstructured":"Jing ZC, Jiang X, Wu BX, Xu XQ, Wu Y, Ma CR, Wang Y, Yang YJ, Pu JL, Gao W (2009) Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart 95(18):1531\u20131536. doi: 10.1136\/hrt.2009.169417","journal-title":"Heart"},{"issue":"2","key":"1323_CR21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1291\/hypres.29.123","volume":"29","author":"K Aizawa","year":"2006","unstructured":"Aizawa K, Hanaoka T, Kasai H, Kogashi K, Kumazaki S, Koyama J, Tsutsui H, Yazaki Y, Watanabe N, Kinoshita O, Ikeda U (2006) Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 29(2):123\u2013128. doi: 10.1291\/hypres.29.123","journal-title":"Hypertens Res"},{"key":"1323_CR22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-7120-3-26","volume":"3","author":"N Jochmann","year":"2005","unstructured":"Jochmann N, Kiecker F, Borges AC, Hofmann MA, Eddicks S, Sterry W, Baumann G, Trefzer U (2005) Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 3:26. doi: 10.1186\/1476-7120-3-26","journal-title":"Cardiovasc Ultrasound"},{"issue":"1","key":"1323_CR23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0310057X0703500113","volume":"35","author":"M Giacomini","year":"2007","unstructured":"Giacomini M, Borotto E, Bosotti L, Denkewitz T, Reali-Forster C, Carlucci P, Centanni S, Mantero A, Iapichino G (2007) Vardenafil and weaning from inhaled nitric oxide: effect on pulmonary hypertension in ARDS. Anaesth Intensive Care 35(1):91\u201393","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"1323_CR24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000049770","volume":"40","author":"S Stark","year":"2001","unstructured":"Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM (2001) Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 40(2):181\u2013190","journal-title":"Eur Urol"},{"issue":"1","key":"1323_CR25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s003450000168","volume":"19","author":"T Klotz","year":"2001","unstructured":"Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, Horstmann R, Engelmann R (2001) Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 19(1):32\u201339","journal-title":"World J Urol"},{"issue":"3","key":"1323_CR26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0091270002250604","volume":"43","author":"P Rajagopalan","year":"2003","unstructured":"Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P (2003) Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 43(3):260\u2013267","journal-title":"J Clin Pharmacol"},{"key":"1323_CR27","first-page":"S103","volume":"49","author":"C Steidle","year":"2001","unstructured":"Steidle C, Feldman R, Lettieri J, Agarwal V, Segerson T (2001) Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction (abstract). J Am Geriatr Soc 49:S103","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"1323_CR28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.ijir.3901522","volume":"19","author":"N Mehrotra","year":"2007","unstructured":"Mehrotra N, Gupta M, Kovar A, Meibohm B (2007) The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 19(3):253\u2013264. doi: 10.1038\/sj.ijir.3901522","journal-title":"Int J Impot Res"},{"issue":"9","key":"1323_CR29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0091270005276847","volume":"45","author":"M Gupta","year":"2005","unstructured":"Gupta M, Kovar A, Meibohm B (2005) The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45(9):987\u20131003. doi: 10.1177\/0091270005276847","journal-title":"J Clin Pharmacol"},{"key":"1323_CR30","unstructured":"European Medicines Agency (2009) Levitra-EPAR: Scientific discussion & Summary of Product Characteristics. European Medicines Agency, London"},{"issue":"4","key":"1323_CR31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2125.1987.tb03069.x","volume":"23","author":"K Dickstein","year":"1987","unstructured":"Dickstein K, Till AE, Aarsland T, Tjelta K, Abrahamsen AM, Kristianson K, Gomez HJ, Gregg H, Hichens M (1987) The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Br J Clin Pharmacol 23(4):403\u2013410","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1323_CR32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99(3):306\u2013314. doi: 10.1016\/j.cmpb.2010.01.007","journal-title":"Comput Methods Programs Biomed"},{"key":"1323_CR33","doi-asserted-by":"crossref","unstructured":"Henrohn D, Sandqvist A, Hedeland M, Eger\u00f6d H, Bondesson U, Wikstr\u00f6m G (2012) Acute hemodynamic response in relation to plasma vardenafil levels in patients with pulmonary hypertension. Br J Clin Pharmacol. doi: 10.1111\/j.1365-2125.2012.04303.x","DOI":"10.1111\/j.1365-2125.2012.04303.x"},{"issue":"10","key":"1323_CR34","first-page":"1217","volume":"28","author":"CY Ng","year":"2000","unstructured":"Ng CY, Ghabrial H, Morgan DJ, Ching MS, Smallwood RA, Angus PW (2000) Impaired elimination of propranolol due to right heart failure: drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity. Drug Metab Dispos 28(10):1217\u20131221","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1323_CR35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","volume":"28","author":"F Delco","year":"2005","unstructured":"Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S (2005) Dose adjustment in patients with liver disease. Drug Safe 28(6):529\u2013545","journal-title":"Drug Safe"},{"issue":"10","key":"1323_CR36","first-page":"1254","volume":"21","author":"G Rohde","year":"2001","unstructured":"Rohde G, Wensing G, Unger S, Sachse R (2001) The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, is minimally affected by coadministration with cimetidine or ranitidine. Pharmacotherapy 21(10):1254\u20131254","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1323_CR37","first-page":"418","volume":"22","author":"T Klotz","year":"2002","unstructured":"Klotz T, Bauer RJ, Rohde G (2002) Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20\u00a0mg, a selective PDE5 inhibitor, for the treatment of erectile dysfunction. Pharmacotherapy 22(3):418\u2013418","journal-title":"Pharmacotherapy"},{"key":"1323_CR38","unstructured":"European Medicines Agency (2009) Revatio-EPAR: Scientific discussion & Summary of Product characteristics. European Medicines Agency, London"},{"key":"1323_CR39","unstructured":"European Medicines Agency (2009) Adcirca-EPAR: Scientific discussion & Summary of Product characteristics. European Medicines Agency, London"},{"issue":"Suppl 3","key":"1323_CR40","doi-asserted-by":"crossref","first-page":"iii36","DOI":"10.1093\/rheumatology\/ken485","volume":"48","author":"A Forbes","year":"2009","unstructured":"Forbes A, Marie I (2009) Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 48[Suppl 3]:iii36\u2013iii39","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1323_CR41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/03009748709102917","volume":"16","author":"T Ammitzb\u00f8ll","year":"1987","unstructured":"Ammitzb\u00f8ll T, Hendel L, Kreuzig F, Asboe-Hansen G (1987) Bioavailability of D-penicillamine in relation to gastrointestinal involvement of generalized scleroderma. Scand J Rheumatol 16(2):121\u2013126","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"1323_CR42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/17425255.4.4.413","volume":"4","author":"MJ Scandlyn","year":"2008","unstructured":"Scandlyn MJ, Stuart EC, Rosengren RJ (2008) Sex-specific differences in CYP450 isoforms in humans. Exp Opin Drug Metab Toxicol 4(4):413\u2013424","journal-title":"Exp Opin Drug Metab Toxicol"},{"issue":"1","key":"1323_CR43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57(1):6\u201314","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1323_CR44","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.mjt.0000183719.84390.4d","volume":"14","author":"ES ElDesoky","year":"2007","unstructured":"ElDesoky ES (2007) Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther 14(5):488\u2013498","journal-title":"Am J Ther"},{"issue":"1","key":"1323_CR45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1985.14","volume":"37","author":"KS Channer","year":"1985","unstructured":"Channer KS, Roberts CJ (1985) Effect of delayed esophageal transit on acetaminophen absorption. Clin Pharmacol Ther 37(1):72\u201376","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1323_CR46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","volume":"60","author":"GA Paul","year":"2005","unstructured":"Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR (2005) Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 60(1):107\u2013112. doi: 10.1111\/j.1365-2125.2005.02383.x","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1323_CR47","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","volume":"48","author":"RE Wrishko","year":"2008","unstructured":"Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI (2008) Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 48(5):610\u2013618. doi: 10.1177\/0091270008315315","journal-title":"J Clin Pharmacol"},{"issue":"S5","key":"1323_CR48","first-page":"S173","volume":"15","author":"BE Patterson","year":"2003","unstructured":"Patterson BE, Mitchell MI, Bedding AW, Jewell H, Payne CD, Thomas Forgue S, Phillips DL (2003) Tadalafil and inducers, inhibitors, and substrates of cytochrome P450 isoenzyme 3A4 (CYP3A4). Int J Impot Res 15(S5):S173\u2013S173","journal-title":"Int J Impot Res"},{"issue":"113","key":"1323_CR49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1183\/09059180.00003809","volume":"18","author":"N Galie","year":"2009","unstructured":"Galie N, Negro L, Simonneau G (2009) The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev 18(113):148\u2013153. doi: 10.1183\/09059180.00003809","journal-title":"Eur Respir Rev"},{"issue":"5","key":"1323_CR50","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","volume":"26","author":"MM Hoeper","year":"2005","unstructured":"Hoeper MM, Markevich I, Spiekerkoetter E, Welte T, Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26(5):858\u2013863. doi: 10.1183\/09031936.05.00075305","journal-title":"Eur Respir J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1323-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-012-1323-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1323-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T15:13:34Z","timestamp":1561907614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-012-1323-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,26]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s00228-012-1323-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,26]]}}}